320 related articles for article (PubMed ID: 37723839)
1. Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing.
Whitley JA; Cai H
J Extracell Vesicles; 2023 Sep; 12(9):e12343. PubMed ID: 37723839
[TBL] [Abstract][Full Text] [Related]
2. Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing.
Yao X; Lyu P; Yoo K; Yadav MK; Singh R; Atala A; Lu B
J Extracell Vesicles; 2021 Mar; 10(5):e12076. PubMed ID: 33747370
[TBL] [Abstract][Full Text] [Related]
3. Encapsulating Cas9 into extracellular vesicles by protein myristoylation.
Whitley JA; Kim S; Lou L; Ye C; Alsaidan OA; Sulejmani E; Cai J; Desrochers EG; Beharry Z; Rickman CB; Klingeborn M; Liu Y; Xie ZR; Cai H
J Extracell Vesicles; 2022 Apr; 11(4):e12196. PubMed ID: 35384352
[TBL] [Abstract][Full Text] [Related]
4. Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading.
Liang Y; Iqbal Z; Wang J; Xu L; Xu X; Ouyang K; Zhang H; Lu J; Duan L; Xia J
Biomater Sci; 2022 Jul; 10(15):4095-4106. PubMed ID: 35766814
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo.
Walther J; Porenta D; Wilbie D; Seinen C; Benne N; Yang Q; de Jong OG; Lei Z; Mastrobattista E
Eur J Pharm Biopharm; 2024 Mar; 196():114207. PubMed ID: 38325664
[TBL] [Abstract][Full Text] [Related]
6. Small extracellular vesicle-mediated CRISPR-Cas9 RNP delivery for cardiac-specific genome editing.
Mun D; Kang JY; Kim H; Yun N; Joung B
J Control Release; 2024 May; 370():798-810. PubMed ID: 38754633
[TBL] [Abstract][Full Text] [Related]
7. Small extracellular vesicles (sEVs)-based gene delivery platform for cell-specific CRISPR/Cas9 genome editing.
Dubey S; Chen Z; Jiang YJ; Talis A; Molotkov A; Ali A; Mintz A; Momen-Heravi F
Theranostics; 2024; 14(7):2777-2793. PubMed ID: 38773978
[TBL] [Abstract][Full Text] [Related]
8. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.
Zhang S; Shen J; Li D; Cheng Y
Theranostics; 2021; 11(2):614-648. PubMed ID: 33391496
[TBL] [Abstract][Full Text] [Related]
9. Extracellular vesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin-kexin type 9 (Pcsk9) in primary mouse hepatocytes.
Ilahibaks NF; Kluiver TA; de Jong OG; de Jager SCA; Schiffelers RM; Vader P; Peng WC; Lei Z; Sluijter JPG
J Extracell Vesicles; 2024 Jan; 13(1):e12389. PubMed ID: 38191764
[TBL] [Abstract][Full Text] [Related]
10. Packaging and Uncoating of CRISPR/Cas Ribonucleoproteins for Efficient Gene Editing with Viral and Non-Viral Extracellular Nanoparticles.
Mazurov D; Ramadan L; Kruglova N
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992399
[TBL] [Abstract][Full Text] [Related]
11. Preparation of NanoMEDIC Extracellular Vesicles to Deliver CRISPR-Cas9 Ribonucleoproteins for Genomic Exon Skipping.
Watanabe K; Gee P; Hotta A
Methods Mol Biol; 2023; 2587():427-453. PubMed ID: 36401042
[TBL] [Abstract][Full Text] [Related]
12. Development of CRISPR/Cas Delivery Systems for In Vivo Precision Genome Editing.
Chen Y; Ping Y
Acc Chem Res; 2023 Aug; 56(16):2185-2196. PubMed ID: 37525893
[TBL] [Abstract][Full Text] [Related]
13. Extracellular vesicles as a potential delivery platform for CRISPR-Cas based therapy in epithelial ovarian cancer.
Godbole N; Quinn A; Carrion F; Pelosi E; Salomon C
Semin Cancer Biol; 2023 Nov; 96():64-81. PubMed ID: 37820858
[TBL] [Abstract][Full Text] [Related]
14. Engineered Extracellular Vesicle-Delivered CRISPR/CasRx as a Novel RNA Editing Tool.
Li T; Zhang L; Lu T; Zhu T; Feng C; Gao N; Liu F; Yu J; Chen K; Zhong J; Tang Q; Zhang Q; Deng X; Ren J; Zeng J; Zhou H; Zhu J
Adv Sci (Weinh); 2023 Apr; 10(10):e2206517. PubMed ID: 36727818
[TBL] [Abstract][Full Text] [Related]
15. Poly-sgRNA/siRNA ribonucleoprotein nanoparticles for targeted gene disruption.
Ha JS; Lee JS; Jeong J; Kim H; Byun J; Kim SA; Lee HJ; Chung HS; Lee JB; Ahn DR
J Control Release; 2017 Mar; 250():27-35. PubMed ID: 28167287
[TBL] [Abstract][Full Text] [Related]
16. Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles.
Huang X; Li A; Xu P; Yu Y; Li S; Hu L; Feng S
J Nanobiotechnology; 2023 Jun; 21(1):184. PubMed ID: 37291577
[TBL] [Abstract][Full Text] [Related]
17. Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy.
Ahmadi SE; Soleymani M; Shahriyary F; Amirzargar MR; Ofoghi M; Fattahi MD; Safa M
Cancer Gene Ther; 2023 Jul; 30(7):936-954. PubMed ID: 36854897
[TBL] [Abstract][Full Text] [Related]
18. Different Methods of Delivering CRISPR/Cas9 Into Cells.
Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
[TBL] [Abstract][Full Text] [Related]
19. Harnessing CRISPR/Cas9 for Enhanced Disease Resistance in Hot Peppers: A Comparative Study on
Park JH; Kim H
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069102
[TBL] [Abstract][Full Text] [Related]
20. [Genome editing in plants directed by CRISPR/Cas ribonucleoprotein complexes].
Li X; Shi W; Geng LZ; Xu JP
Yi Chuan; 2020 Jun; 42(6):556-564. PubMed ID: 32694114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
